ADC skin toxicity is common, clinically relevant, and still difficult to predict before the clinic. Join us at the 16th World ADC London Summit to see how our human ex vivo skin platform improves translational safety assessment. Principal Scientist Jason Holsapple, PhD, will present our latest work modeling ADC-induced cutaneous toxicity using viable human skin tissue. 🚀 FEATURED PRESENTATION An advanced human skin research platform enabling long-term, immune-competent evaluation of ADC-induced cutaneous toxicity Mark Your Calendar Pre-Conference Day, 3rd Toxicity Day 📅 Monday, February 23 ⏰10:30 AM (Local) Key highlights ✅ Viable human skin culture maintained for ~1 month with intact immune function ✅ Reproduces clinically relevant ADC skin injury ✅ Early screening to help de-risk biologics and ADC programs 🔬 POSTER PRESENTATION (No. 36) An ex vivo human skin platform for evaluating ADC-induced skin toxicity beyond preclinical limits Mark Your Calendar Conference Day Two 📅 Wednesday, February 25 ⏰ 10:00 - 11:00 AM (Local) Exhibition Hall #WorldADCEurope #ADC #DrugSafety #ToxicityTesting #Biologics #TranslationalMedicine
About us
Outer Biosciences aims to improve human health by discovering bioactives from underexplored natural sources. Outer’s platform is comprised of the world’s most clinically relevant, long-lasting models of human skin, multimodal data analysis and predictive machine learning. With their evidence-based approach, the company is identifying safe and efficacious bioactive compounds at an unprecedented scale for use in health and beauty products. Outer Biosciences envisions a future in which science reveals the power of nature to heal us all.
- Website
-
https://www.outerbio.com/
External link for Outer Biosciences
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Type
- Privately Held
Employees at Outer Biosciences
Updates
-
We are proud to be a Programme Partner at the 16th World ADC London Summit, February 23–26. At this meeting, we will share how our advanced ex vivo human skin platform supports ADC development by enabling: -Earlier identification of dermatologic toxicity risk. -Mechanistic understanding of target-related skin injury. -Better derisking before clinical evaluation. 🌏 Meet our team in London! Stanley King II, PhD, Co-founder & Chief Business Officer Jason Holsapple, PhD, Principal Scientist Let's discuss how we can advance oncology innovation to accelerate safer, more effective drug development together! World ADC Event Series #WorldADC #ADCs #OncologyInnovation #DrugDevelopment #Dermatology
-
-
We are excited and honored to showcase our research at the 6th ISDS - Inflammatory Skin Disease Summit in New York City this week. Our Senior Scientist, Jason Holsapple, will share how our platform is used in translational research. If you’re attending or interested in our presentation send us a message. #ISDS2025